Paraphimosis is a urological emergency characterized by the inability to reduce a retracted foreskin over the glans penis, leading to vascular congestion, edema, and potential tissue necrosis. While paraphimosis can result from local trauma, poor hygiene, or iatrogenic causes, it is increasingly recognized as a clinical manifestation associated with underlying systemic disease, particularly diabetes mellitus.

Diabetes mellitus, especially when undiagnosed or poorly controlled, exerts profound effects on local tissue immunity, wound healing, and susceptibility to infection and inflammation. Chronic hyperglycemia impairs neutrophil function, reduces chemotaxis, and disrupts the integrity of the microvasculature. These changes create a pathogen-friendly environment, predisposing to recurrent balanoposthitis, preputial edema, and fibrosis. Over time, these processes increase the risk of both phimosis (inability to retract the foreskin) and paraphimosis (inability to reduce the retracted foreskin). Hyperglycemia-induced microvascular changes further promote capillary leakage and tissue swelling, while impaired immune responses and poor tissue repair facilitate persistent inflammation and infection.

Several clinical studies have highlighted the strong association between acquired preputial disorders and diabetes. In a prospective cohort, all adults presenting with phimosis and preputial fissures were found to have diabetes, with many cases previously undiagnosed. Another study reported that up to 26 percent of men with acquired phimosis had diabetes, and 12 percent of these were newly diagnosed at the time of presentation. These findings underscore the importance of considering diabetes in the differential diagnosis of adult men presenting with preputial complications, including paraphimosis. Notably, paraphimosis may be the first clinical clue to undiagnosed diabetes, particularly in patients with subtle or absent classic symptoms of hyperglycemia.

Given the high prevalence of undiagnosed diabetes in adults with paraphimosis or acquired phimosis, routine screening for diabetes is strongly recommended in this population. Laboratory-based screening modalities such as fasting plasma glucose, hemoglobin A1c (HbA1c), or oral glucose tolerance test (OGTT) are sensitive and effective for detecting both overt and subclinical diabetes. Early identification of diabetes in patients with paraphimosis allows for prompt initiation of glycemic control, which can prevent further genitourinary complications, reduce the risk of infection, and improve wound healing outcomes.

Screening is particularly crucial in high-risk groups, including older adults, individuals with obesity, and those with a family history of diabetes. In these populations, the threshold for screening should be even lower, as the risk of both diabetes and its complications is elevated.

For clinicians, the presentation of paraphimosis in an adult should prompt not only urgent urological management but also a thorough evaluation for underlying diabetes. Addressing hyperglycemia and optimizing glycemic control are essential components of comprehensive care, reducing the risk of recurrence and improving overall patient outcomes. Patient education regarding the link between diabetes and genitourinary health should be incorporated into routine counseling.

In summary, paraphimosis is not merely a local urological issue but may serve as an early warning sign of undiagnosed diabetes mellitus. Routine diabetes screening in adults presenting with paraphimosis is evidence-based, cost-effective, and critical for preventing further complications. Early detection and management of diabetes in this context can significantly improve both genitourinary and systemic health outcomes.

Shirisha Kamidi is a board-certified internal medicine physician and hospitalist at Baptist Memorial Hospital–Desoto in Southaven, Mississippi. She completed her internal medicine–pediatrics residency at Oakland University William Beaumont Hospital in Michigan after earning her medical degree from Kakatiya Medical College in India.

Dr. Kamidi is passionate about improving patient outcomes and hospital efficiency through quality-improvement initiatives, including reducing hospital-acquired Clostridium difficile infections and enhancing care for myocardial infarction (MI) and congestive heart failure (CHF) patients. As an Epic Physician Builder, she enjoys optimizing clinical workflows to support both providers and patients. She also contributes to evidence-based practice and academic collaboration, serving as a coauthor of the publication “Outcome on Reinstitution of Anticoagulation Following Intracranial Hemorrhage: A Single Institutional Analysis.”

In addition to her clinical work, she serves as teaching faculty and mentors residents, medical students, and high-school students exploring healthcare careers. She is actively involved in the American College of Physicians, the Society of Hospital Medicine, and the American College of Lifestyle Medicine, and she serves on SHM’s Hospital Quality and Patient Safety Advocates Council (2025–2026).

Outside of medicine, she finds balance through yoga, meditation, swimming, and traveling, which aligns with her belief in holistic well-being and lifelong growth.